PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29124230-14 2015 In addition, SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor) significantly suppressed the expression of TNF-alpha and IL-8 in LPS-stimulated THP-1 cells. SB 203580 13-21 C-X-C motif chemokine ligand 8 Homo sapiens 124-128 26848751-6 2016 IL-1beta-induced the degradation of IkappaBalpha, and the phosphorylation of p38 and ERK, and the IL-1beta-induced expression of IL-8 mRNA was inhibited by specific inhibitors, such as BAY-117085 for NF-kB, SB203580 for p38, and PD98059 for ERK. SB 203580 207-215 C-X-C motif chemokine ligand 8 Homo sapiens 129-133 25515776-9 2015 The production of IL6 and IL8 was also suppressed by p38 inhibitor SB203580. SB 203580 67-75 C-X-C motif chemokine ligand 8 Homo sapiens 26-29 24463979-8 2014 Ten micromoles of SB203580, an inhibitor of p38, almost completely suppressed the production of IL-8 from acetylated low-density lipoprotein-loaded THP-1 macrophages and accelerated cholesterol efflux. SB 203580 18-26 C-X-C motif chemokine ligand 8 Homo sapiens 96-100 24522860-6 2014 M3 mAChR-mediated IL-8 expression was almost completely inhibited by the NF-kappaB inhibitor BAY11-7082 and, to a lesser extent, by U0126, SB203580, and SP600125, which are inhibitors for ERK1/2, p38, and JNK, respectively. SB 203580 139-147 C-X-C motif chemokine ligand 8 Homo sapiens 18-22 24126532-7 2014 Inhibitors of p38 MAPK (SB203580) and Erk1/2 (PD98059) blocked HbR-induced IL-8 production. SB 203580 24-32 C-X-C motif chemokine ligand 8 Homo sapiens 75-79 24739825-7 2014 Furthermore, after pretreatment of Ec109 cells with the specific p38 MAPK inhibitor SB203580, Ec109 cells proliferation and IL-8 secretion were inhibited. SB 203580 84-92 C-X-C motif chemokine ligand 8 Homo sapiens 124-128 24126532-11 2014 Combined pretreatment with an inhibitor of NF-kappaB (BAY11-7082) and SB203580 was more efficient in inhibiting the ability of HbR to induce IL-8 production than pretreatment with either BAY11-7082 or SB203580 alone. SB 203580 70-78 C-X-C motif chemokine ligand 8 Homo sapiens 141-145 22721959-7 2012 On the other hand, PD98059 and SB203580 suppressed the toxin-induced production of IL-8. SB 203580 31-39 C-X-C motif chemokine ligand 8 Homo sapiens 83-87 23670201-12 2013 As signal transduction pathway involvement, in both THP-1 and A549 cells, PM2.5-induced IL-8 release could be completely blocked by the selective inhibitor SB203580, indicating a role of p38 MAPK activation. SB 203580 156-164 C-X-C motif chemokine ligand 8 Homo sapiens 88-92 22788664-12 2013 Moreover, both the promoter activity and the LPS-induced release of IL-8 were diminished upon the administration of U0126 and SB203580, but not SP600125. SB 203580 126-134 C-X-C motif chemokine ligand 8 Homo sapiens 68-72 23484689-3 2013 After treatment of K562 cells with p38 inhibitor SB203580, the IL-8 expression level was decreased by real-time quantitative PCR. SB 203580 49-57 C-X-C motif chemokine ligand 8 Homo sapiens 63-67 23484689-7 2013 The down-regulation of IL-8 expression induced by cariporide treatment was partially restored after K562 cells were treated with p38 inhibitor SB203580. SB 203580 143-151 C-X-C motif chemokine ligand 8 Homo sapiens 23-27 22721959-8 2012 Treatment of the cells with PD98059 resulted in inhibition of IL-8 mRNA expression induced by the toxin and that with SB203580 led to a decrease in the stabilization of IL-8 mRNA. SB 203580 118-126 C-X-C motif chemokine ligand 8 Homo sapiens 169-173 21545687-5 2012 Tumour necrosis factor-alpha (TNF-alpha) significantly induced phosphorylation of p38 MAPK, ERK, Akt and production of IL-8 from HCC cells, which were prevented by SB203580 (p38 MAPK inhibitor), PD98059 (ERK inhibitor), LY294002 and Wortmannin (PI3K inhibitor) and SB328437 (CCR3 inhibitor). SB 203580 164-172 C-X-C motif chemokine ligand 8 Homo sapiens 119-123 22618201-6 2012 The p38 inhibitor SB203580 and the STAT1 inhibitor EGCG blocked CM-induced IL-8 production at both early and late time periods. SB 203580 18-26 C-X-C motif chemokine ligand 8 Homo sapiens 75-79 21932059-6 2012 Preincubation with ERK1/2 inhibitor (PD98059) or p38 inhibitor (SB203580) markedly blocked DEHP-stimulated activation of ICAM-1 and IL-8. SB 203580 64-72 C-X-C motif chemokine ligand 8 Homo sapiens 132-136 23046936-9 2012 (3) Dexamethasone (1 mumol/L) and SB203580 (20 mumol/L) significantly decreased both the mRNA and protein production of IL-8 and IP-10 induced by co-stimulation of 0.1 mug/mL poly (I:C) and 10 mug/mL LPS compared with the control group and control+DMSO group respectively (P<0.01 and P<0.05). SB 203580 34-42 C-X-C motif chemokine ligand 8 Homo sapiens 120-124 21161531-6 2012 Furthermore, IL-6 and IL-8 expression was quantified by real-time polymerase chain reaction (RT-PCR) and ELISAs from cells which were exposed to SB203580, U0126 and NaHS and stimulated by IL-1beta. SB 203580 145-153 C-X-C motif chemokine ligand 8 Homo sapiens 22-26 22675954-7 2012 The increase of IL-8 stimulated by IL-1alpha or TNF-alpha was also suppressed by treatment with U0126 or SB203580. SB 203580 105-113 C-X-C motif chemokine ligand 8 Homo sapiens 16-20 22048642-7 2012 Consistently, CSM-induced IL-8 release was blocked by SB203580, U0126, or MEK1 small interfering RNA (siRNA) but not SP600125. SB 203580 54-62 C-X-C motif chemokine ligand 8 Homo sapiens 26-30 22080750-7 2012 PGE(2)-induced IL-8 production was accompanied by p38 phosphorylation and was significantly inhibited by a p38 inhibitor, SB-203580, but not by an ERK1/2 inhibitor, U-0126, or a JNK inhibitor, SP-600125. SB 203580 122-131 C-X-C motif chemokine ligand 8 Homo sapiens 15-19 21796149-10 2011 Treatment with the ERK inhibitor PD98059 and with the p38 kinase inhibitor SB203580 effectively suppressed beta-glucan-induced IL-8 production by NHEKs. SB 203580 75-83 C-X-C motif chemokine ligand 8 Homo sapiens 127-131 22525504-7 2011 p38 MAPK inhibitor (SB203580) could significantly inhibit IL-8 production in a dose-dependent manners (F = 65.47, P < 0.01), and partially inhibited NF-kB p65 nuclear translocation in a dose-dependent manner (F=141.20, P < 0.05). SB 203580 20-28 C-X-C motif chemokine ligand 8 Homo sapiens 58-62 20739465-10 2011 Hypertonicity-induced increases in IL-6 and IL-8 releases were suppressed by exposure to capsazepine, AG 1478, ERK inhibitor PD 98059, p38 inhibitor SB 203580, or NF-kappaB inhibitor PDTC. SB 203580 149-158 C-X-C motif chemokine ligand 8 Homo sapiens 44-48 21193553-7 2011 Addition of the p38 inhibitor SB203580 to Dianeal resulted in dampened IL-8 release (-55%; p < 0.05) and basal HSP70 expression, and unchanged LDH release. SB 203580 30-38 C-X-C motif chemokine ligand 8 Homo sapiens 71-75 21468084-7 2011 Further, the over-expression of LPS-induced IL-8 mRNA in HUVECs was suppressed by a p38 MAPK inhibitor (SB203580, 25 mumol/L) or a phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002, 50 mumol/L). SB 203580 104-112 C-X-C motif chemokine ligand 8 Homo sapiens 44-48 21637924-10 2011 Furthermore, IL-8 mRNA expression was inhibited significantly after co-incubation with PD98059 (ERK inhibitor) and SB203580 (p38 inhibitor), respectively. SB 203580 115-123 C-X-C motif chemokine ligand 8 Homo sapiens 13-17 21454676-9 2011 By contrast, direct inhibition of p38 MAPK (inhibitor SB203580) efficiently suppresses IL-8 with potency comparable with dexamethasone. SB 203580 54-62 C-X-C motif chemokine ligand 8 Homo sapiens 87-91 21454676-10 2011 Similar to dexamethasone, SB203580 decreases IL-8 mRNA stability. SB 203580 26-34 C-X-C motif chemokine ligand 8 Homo sapiens 45-49 21177635-8 2011 ERK1/2 pathway inhibitor, UO126, failed IL-8 promoter activity, whereas p38 MAPK inhibitor, SB203580, decreased the stabilization of IL-8 messenger RNA following V. parahaemolyticus infection. SB 203580 92-100 C-X-C motif chemokine ligand 8 Homo sapiens 133-137 20731619-10 2010 Inactivation of ERK signaling pathways by PD98059 effectively blocked IL-6, -8, and -10 induction by WTC2.5; the p38 kinase inhibitor SB203580 significantly decreased induction of IL-8 and -10. SB 203580 134-142 C-X-C motif chemokine ligand 8 Homo sapiens 180-192 20304034-10 2010 Further, the adhesin induced IL-8 secretion was reduced in the presence of the inhibitors of MEK (PD098059), p38-MAPK (SB203580) and JAK (-2,-3)/STAT-3 pathway (AG490). SB 203580 119-127 C-X-C motif chemokine ligand 8 Homo sapiens 29-33 19376214-6 2009 Phosphorylated forms of mitogen-activated protein kinases (MAPKs)-including extracellular signal-regulated protein kinase (ERK), c-Jun NH(2)-terminal kinase, and p38-increased after NaF exposure, while treatment with the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 markedly suppressed COX-2 expression. SB 203580 275-283 C-X-C motif chemokine ligand 8 Homo sapiens 182-185 19917067-11 2009 While SLIGKV-induced IL-8 formation was reduced by both SB203580 and YM-254890, the response to K-14585 was sensitive to SB203580 but not YM-254890. SB 203580 56-64 C-X-C motif chemokine ligand 8 Homo sapiens 21-25 19648110-4 2009 Since NF-kappaB-dependent transcription and IL-8 protein, mRNA, and unspliced RNA (a surrogate of transcription rate) are sensitive to p38 MAPK inhibitors (SB203580 and SB239063), we explored the role of MKP-1 in repression of these outputs. SB 203580 156-164 C-X-C motif chemokine ligand 8 Homo sapiens 44-48 19781372-8 2009 In addition, preincubation of EPCs with SB203580, an inhibitor of p38 mitogen-activated protein kinase (MAPK) decreased CRP inhibition of IL-8 mRNA expression at 12 hours in EPCs. SB 203580 40-48 C-X-C motif chemokine ligand 8 Homo sapiens 138-142 19898747-5 2010 Further, pretreatment of these cells with the highly specific MEK inhibitor (PD 098059), the JNK inhibitor (SP 600125), and the p38MAPK inhibitor (SB 203580) resulted in inhibition of the IL-8 secretion by EAEC (wild type as well as plasmid cured)-infected INT-407 cells. SB 203580 147-156 C-X-C motif chemokine ligand 8 Homo sapiens 188-192 20050188-10 2009 BK-induced IL-8 release was attenuated by inhibitors of phospholipase C (U73122), p38 (SB203580), JNK (SP600125), ERK 1/2 (PD98059) MAPKs, phosphoinositide 3-kinase (LY294002), NF-kappaB (BAY-117085) and by the glucocorticoid dexamethasone. SB 203580 87-95 C-X-C motif chemokine ligand 8 Homo sapiens 11-15 19709445-11 2009 The IL-8 induced-IL-8 mRNA expression was inhibited by PD98059 (a MEK inhibitor) or SB203580 (a p38 MAPK inhibitor). SB 203580 84-92 C-X-C motif chemokine ligand 8 Homo sapiens 4-8 19709445-11 2009 The IL-8 induced-IL-8 mRNA expression was inhibited by PD98059 (a MEK inhibitor) or SB203580 (a p38 MAPK inhibitor). SB 203580 84-92 C-X-C motif chemokine ligand 8 Homo sapiens 17-21 19709445-13 2009 The inhibitory effect of IL-8 was eliminated by either PD 98059 or SB203580. SB 203580 67-75 C-X-C motif chemokine ligand 8 Homo sapiens 25-29 19373630-11 2009 SB203580, PD98059, and wedeloactone decreased IL-8 production stimulated by Na(2)SO(3) (p < 0.01). SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 46-50 19558546-9 2009 The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38. SB 203580 87-95 C-X-C motif chemokine ligand 8 Homo sapiens 17-21 19558546-9 2009 The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38. SB 203580 87-95 C-X-C motif chemokine ligand 8 Homo sapiens 244-248 19074641-8 2009 The p38 MAPK inhibitor SB-203580 did not inhibit IL-6 expression but exerted a stronger inhibitory effect on IL-8 expression. SB 203580 23-32 C-X-C motif chemokine ligand 8 Homo sapiens 109-113 18277946-4 2008 Both PAR2-AP and the endogenous PAR2 activator trypsin caused concentration- and time-dependent increase in endothelial IL-8 production, and this effect was concentration dependently and selectively attenuated by the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580. SB 203580 271-279 C-X-C motif chemokine ligand 8 Homo sapiens 120-124 18941244-8 2008 The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17. SB 203580 35-43 C-X-C motif chemokine ligand 8 Homo sapiens 192-197 18941244-8 2008 The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17. SB 203580 35-43 C-X-C motif chemokine ligand 8 Homo sapiens 315-320 18662754-6 2008 The induction of IL-8 by titanium dioxide nanoparticles was inhibited by the pre-treatment with SB203580 and PD98059, which means that the IL-8 was induced through p38 mitogen-activated protein kinase (MAPK) pathway and/or extracellular signal (ERK) pathway. SB 203580 96-104 C-X-C motif chemokine ligand 8 Homo sapiens 17-21 18974961-12 2008 Pretreatment with PD98059 (ERK inhibitor), SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) decreased the IL-8 production induced by H(2)O(2). SB 203580 43-51 C-X-C motif chemokine ligand 8 Homo sapiens 111-115 18662754-6 2008 The induction of IL-8 by titanium dioxide nanoparticles was inhibited by the pre-treatment with SB203580 and PD98059, which means that the IL-8 was induced through p38 mitogen-activated protein kinase (MAPK) pathway and/or extracellular signal (ERK) pathway. SB 203580 96-104 C-X-C motif chemokine ligand 8 Homo sapiens 139-143 17786963-6 2008 Treatment with the p38 inhibitor SB203580 attenuated the HNP-induced IL-8 production only in monocytes. SB 203580 33-41 C-X-C motif chemokine ligand 8 Homo sapiens 69-73 17724435-10 2008 SB203580 also prevented the CytoMix-induced permeability increase and reduced NO, IL-6, and IL-8 levels. SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 92-96 18276593-9 2008 The p38 mitogen-activated protein kinase inhibitor SB203580 blocked IL-8 secretion but not ICAM-1 expression, whereas the PI3K inhibitor wortmannin was ineffective in both responses. SB 203580 51-59 C-X-C motif chemokine ligand 8 Homo sapiens 68-72 18494145-13 2008 By Western blot analysis we could indeed demonstrate p38 activation by all chemical allergens tested and, using the selective p38 MAPK inhibitor SB203580, a significant modulation of allergen-induced IL-8 release could be achieved in all cases. SB 203580 145-153 C-X-C motif chemokine ligand 8 Homo sapiens 200-204 16434099-7 2006 Treatment of 28SC cells with the pyridylimidizole analogue SB203580, a known inhibitor of p38 MAPK, suppressed ricin-mediated IL-8 release. SB 203580 59-67 C-X-C motif chemokine ligand 8 Homo sapiens 126-130 17700564-7 2007 Moreover, IL-33-mediated IL-8 production by HUCBMCs was markedly reduced by the p38 MAPK inhibitor, SB203580. SB 203580 100-108 C-X-C motif chemokine ligand 8 Homo sapiens 25-29 16937467-10 2006 Although all three MAP kinase family members were phosphorylated in response to TNF-alpha, a selective inhibitor of p38 kinase SB203580 only could inhibit both NF-kappaB-dependent transcriptional activity and IL-8 and CCL20 production, suggesting a potential link between p38 kinase and NF-kappaB-dependent pathways in AGS cells. SB 203580 127-135 C-X-C motif chemokine ligand 8 Homo sapiens 209-213 16761312-5 2006 sPLA(2) induced the phosphorylation of the MAPK p38 and ERK1/2, and inhibition of these kinases by SB203580 and PD98059, respectively, reduced TNF-alpha and CXCL8 release. SB 203580 99-107 C-X-C motif chemokine ligand 8 Homo sapiens 157-162 18639962-11 2008 Inhibition of ERK1/2, JNK1/2 and p38 MAPK with PD98059, SP600125 and SB203580, respectively, led to the suppression of the shear stress-induced IL-8 gene expression (P<0.01), which was also blocked by JNK1/2 siRNA (small interfering RNA) (P<0.01). SB 203580 69-77 C-X-C motif chemokine ligand 8 Homo sapiens 144-148 17876544-10 2007 Inhibitors for ERK (PD98059 and U0216) and p38 MAPK (SB203580) significantly reduced the IL-17F-induced IL-6, IL-8, LIF, MMP-1, and MMP-3 secretion. SB 203580 53-61 C-X-C motif chemokine ligand 8 Homo sapiens 110-114 17460254-9 2007 The MMC-related IL-8 and MCP-1 expression was inhibited by both a p38 inhibitor (SB203580) and an ERK inhibitor (PD98059). SB 203580 81-89 C-X-C motif chemokine ligand 8 Homo sapiens 16-20 16678783-7 2006 Furthermore, the p38 mitogen-activated protein (MAP) kinase inhibitor SB 203580 reduced IL-8 production induced by IL-1beta as well as by the combination of EGF and IL-1beta but had no effect on EGF-induced IL-8 production. SB 203580 70-79 C-X-C motif chemokine ligand 8 Homo sapiens 88-92 16364386-3 2006 Expression of IL-8 hnRNA, mRNA and protein correlated with p38 phosphorylation and was completely abrogated by the p38 MAPK inhibitor SB203580. SB 203580 134-142 C-X-C motif chemokine ligand 8 Homo sapiens 14-18 16684953-9 2006 The decay of IL-8 mRNA transcripts proceeded at a significantly faster rate when cells were pretreated with the p38 MAPK inhibitor SB-203580 (-0.05763 +/- 0.01964, t(1/2) = 12.0 h), compared with vehicle (-0.01030 +/- 0.007963, t(1/2) = 67.3 h) [results are expressed as decay constant (means +/- SE) and half-life (t(1/2) in h): P < 0.05]. SB 203580 131-140 C-X-C motif chemokine ligand 8 Homo sapiens 13-17 16388870-6 2006 Addition of p38 MAPK inhibitor, SB-203580 and NF-kappaB inhibitor Bay 11-7082, suppressed IBDV-induced NO production and mRNA expression of iNOS, IL-8 and COX-2. SB 203580 32-41 C-X-C motif chemokine ligand 8 Homo sapiens 146-150 16690053-4 2006 The chymase-induced IL-8 release was inhibited by pertussis toxin as well as U0126 (an inhibitor for extracellular signal-regulated kinase pathway) and SB203580 (p38 inhibitor), suggesting that the chymase-induced IL-8 production is mediated by G protein-coupled receptor and mitogen-activated protein kinases. SB 203580 152-160 C-X-C motif chemokine ligand 8 Homo sapiens 20-24 16690053-4 2006 The chymase-induced IL-8 release was inhibited by pertussis toxin as well as U0126 (an inhibitor for extracellular signal-regulated kinase pathway) and SB203580 (p38 inhibitor), suggesting that the chymase-induced IL-8 production is mediated by G protein-coupled receptor and mitogen-activated protein kinases. SB 203580 152-160 C-X-C motif chemokine ligand 8 Homo sapiens 214-218 16085674-7 2006 The p38 MAP kinase inhibitor SB-203580 increased CAM-induced IL-8 release (P < 0.001), and the c-jun NH2-terminal kinase inhibitor SP-600125 had no effect on IL-8. SB 203580 29-38 C-X-C motif chemokine ligand 8 Homo sapiens 61-65 16197369-7 2006 The LPA-induced secretion of IL-8 was blocked by the p38 MAPK inhibitor SB203580, by p38 MAPK siRNA (small interfering RNA), and by the JNK inhibitor JNK(i) II, but not by the MEK (MAPK/ERK kinase) inhibitor, PD98059. SB 203580 72-80 C-X-C motif chemokine ligand 8 Homo sapiens 29-33 16197369-9 2006 Furthermore, SB203580 attenuated LPA-dependent phosphorylation of IkappaB (inhibitory kappaB), NF-kappaB and phospho-p38 translocation to the nucleus, NF-kappaB transcription and IL-8 promoter-mediated luciferase reporter activity, without affecting the JNK pathway and AP-1 transcription. SB 203580 13-21 C-X-C motif chemokine ligand 8 Homo sapiens 179-183 16085674-11 2006 The p38 MAP kinase inhibitor, SB-203580 increased ERK phosphorylation and IL-8 secretion. SB 203580 30-39 C-X-C motif chemokine ligand 8 Homo sapiens 74-78 16263754-5 2005 Moreover, inhibitors of MAPK (U0126 and SB203580) significantly reduced the IL-8 production, while the inhibition of NF-kappaB (pyrrolidinedithiocarbamate and retrovirus containing dominant-negative IkappaB alpha plasmid) did not affect the IL-8 expression increased by CpG ODN. SB 203580 40-48 C-X-C motif chemokine ligand 8 Homo sapiens 76-80 16253565-6 2006 The JNK inhibitor SP600125 and the PI3-kinase inhibitor LY294002 significantly blocked the poly(I:C)-induced release of RANTES and IL-8, whereas the p38 MAP kinase inhibitor SB203580 suppressed poly(I:C)-induced secretion of IL-8, but not RANTES. SB 203580 174-182 C-X-C motif chemokine ligand 8 Homo sapiens 225-229 16343928-5 2005 Pretreatment of MAPK inhibitors (PD98059 and SB203580) markedly blocked Ca(2+)-induced IL-8 production from cells, and anti-inflammatory drugs, such as dexamethasone and cyclosporin A, partially inhibited the activation of ERK1/2. SB 203580 45-53 C-X-C motif chemokine ligand 8 Homo sapiens 87-91 16697690-7 2006 p38 MAPK pathway appears also being involved as SB203580, a selective inhibitor of p38 MAPK inhibit phosphorylation of p38 MAPK and thrombin-induced IL-8 secretion. SB 203580 48-56 C-X-C motif chemokine ligand 8 Homo sapiens 149-153 15701058-9 2005 Furthermore, specific MAPK inhibitors (PD98059, SB203580 and SP600125) inhibited the expression of IL-8 mRNA induced by CRP (50 microg/ml). SB 203580 48-56 C-X-C motif chemokine ligand 8 Homo sapiens 99-103 16220077-7 2005 The inhibitors of ERK 1/2 (PD98059), p38 (SB203580) MAPK, and NF-kappaB (PDTC and MG132) significantly decreased C-reactive protein-induced IL-8 secretion in human monocytes. SB 203580 42-50 C-X-C motif chemokine ligand 8 Homo sapiens 140-144 15982617-8 2005 Using SB203580, a specific inhibitor of p38 MAPK, we detected a concentration-dependent inhibition of IL-17--induced IL-8 production with a maximal decrease of 63 +/- 5% (n=8, p<0.01). SB 203580 6-14 C-X-C motif chemokine ligand 8 Homo sapiens 117-121 15606618-6 2005 IkappaB-alpha phosphorylation inhibitor, BAY 11-7082, and p38 MAPK inhibitor, SB 203580 could decrease the release of IL-8, IP-10 and MCP-1 in the coculture. SB 203580 78-87 C-X-C motif chemokine ligand 8 Homo sapiens 118-122 15664665-7 2005 The specific p38 mitogen-activated protein kinase (MAPK) inhibitor SB 203580 reduced IL-8 production stimulated by the combination of BK and IL-1beta as well as the IL-1beta-stimulated IL-8 production. SB 203580 67-76 C-X-C motif chemokine ligand 8 Homo sapiens 85-89 15251176-9 2004 When cells exposed to 200 microM SM were treated with the p38 MAP kinase inhibitor SB203580, the levels of IL-8, IL-6, and TNF-alpha and IL-1beta were significantly decreased when compared with cells that were untreated. SB 203580 83-91 C-X-C motif chemokine ligand 8 Homo sapiens 107-111 15117678-6 2004 Expression of IL-1beta, IL-6, IL-8, and COX-2 mRNA was reduced by 30 microM PP1, an Src family tyrosine kinase inhibitor, and by 25 microM SB-203580, a p38 MAPK inhibitor. SB 203580 139-148 C-X-C motif chemokine ligand 8 Homo sapiens 30-34 15208668-5 2004 Specific inhibitors of MEK-1 (PD980590) and P38 MAPK (SB203580) were found to suppress the IL-8 expression and the IL-8 promoter activity. SB 203580 54-62 C-X-C motif chemokine ligand 8 Homo sapiens 91-95 15208668-5 2004 Specific inhibitors of MEK-1 (PD980590) and P38 MAPK (SB203580) were found to suppress the IL-8 expression and the IL-8 promoter activity. SB 203580 54-62 C-X-C motif chemokine ligand 8 Homo sapiens 115-119 15384255-5 2004 Finally, pre-treatment with a selective p38 MAPK-inhibitor, SB 203580, potently reduced the BLM-induced up-regulation of IL-8 expression but did not show any effect on expression of ICAM-1. SB 203580 60-69 C-X-C motif chemokine ligand 8 Homo sapiens 121-125 15207247-3 2004 In this report, we demonstrate, using two potent and selective inhibitors of MEK activation by Raf-1 (PD-098059) and p38 (SB-203580), that both ERK1/2 and p38 pathways play a key role in the production of IL-8 by porins and LPS. SB 203580 122-131 C-X-C motif chemokine ligand 8 Homo sapiens 205-209 15207247-4 2004 Porin-stimulated expression of activating protein 1 (AP-1) and correlated IL-8 release is also inhibited by PD-098059 or SB-203580 indicating that the Raf-1/MEK1-MEK2/MAPK cascade is required for their activation. SB 203580 121-130 C-X-C motif chemokine ligand 8 Homo sapiens 74-78 15050605-5 2004 The p38 inhibitor SB 203580 resulted in a significant decrease in IL-8 peptide production (p < 0.01). SB 203580 18-27 C-X-C motif chemokine ligand 8 Homo sapiens 66-70 15218990-3 2004 IL-8 production was dependent on phosphorylation of ERK-1 and -2 and p38 MAPK, as examined by PD 098059 (10 microM), an inhibitor of the upstream activator of MAPK kinase (MKK)-1, and SB 203580 (10 microM), an inhibitor of p38 MAPK. SB 203580 184-193 C-X-C motif chemokine ligand 8 Homo sapiens 0-4 14717657-8 2004 SB203580, the specific inhibitor of p38 MAPK, inhibited MTX-induced IL-8 production. SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 68-72 14499342-5 2003 Lipopolysaccharide (LPS)-induced IL-8 production was inhibited by SB203580, but not by the MK2 inhibitory peptide. SB 203580 66-74 C-X-C motif chemokine ligand 8 Homo sapiens 33-37 15023565-6 2004 Although both p38 and ERK 1/2 MAPKs were activated by LDL, only p38 MAPK is responsible for the LDL effects, as evidenced by a complete blockade of IL-8 upregulation by SB203580. SB 203580 169-177 C-X-C motif chemokine ligand 8 Homo sapiens 148-152 15568616-8 2004 This additive effect on IL-8 release was reduced when the cells were also treated with PD-098059, a selective inhibitor of the MEK1 activator and the MAPK cascade, or SB203580, a specific inhibitor of the p38 pathway, or AG490, a specific JAK/STAT pathway inhibitor, providing evidence that there are different signal pathways activated which have a cumulative effect. SB 203580 167-175 C-X-C motif chemokine ligand 8 Homo sapiens 24-28 12600836-5 2003 Furthermore, the PKR inhibitor 2-aminopurine significantly blocked dsRNA-induced RANTES and IL-8 secretion, whereas the p38 mitogen-activated protein kinase inhibitor SB203580 suppressed dsRNA-induced IL-8, but not RANTES. SB 203580 167-175 C-X-C motif chemokine ligand 8 Homo sapiens 201-205 14553834-8 2003 Furthermore, the ERK 1/2 inhibitor, PD98059, and the p38 MAPK inhibitor, SB203580, markedly reduced 8-isoprostane-induced IL-8 expression (mRNA and protein), while inhibition of NF-kappaB activation and translocation had no significant effect on IL-8 expression. SB 203580 73-81 C-X-C motif chemokine ligand 8 Homo sapiens 122-126 14553834-8 2003 Furthermore, the ERK 1/2 inhibitor, PD98059, and the p38 MAPK inhibitor, SB203580, markedly reduced 8-isoprostane-induced IL-8 expression (mRNA and protein), while inhibition of NF-kappaB activation and translocation had no significant effect on IL-8 expression. SB 203580 73-81 C-X-C motif chemokine ligand 8 Homo sapiens 246-250 13679572-6 2003 IL-8 secretion was inhibited by pertussis toxin and a selective p38 kinase inhibitor, SB203580. SB 203580 86-94 C-X-C motif chemokine ligand 8 Homo sapiens 0-4 12857601-7 2003 The p38 mitogen-activated protein kinase inhibitor SB 203580 inhibits the IL-8 mRNA expression and the release of protein from neutrophils. SB 203580 51-60 C-X-C motif chemokine ligand 8 Homo sapiens 74-78 11953364-7 2002 Pretreatment of cells with the highly specific MEK1/2 inhibitor U0126, the p38 inhibitor SB203580, and/or the proteasome inhibitor ALLN led to inhibition of the IL-8 secretion induced in EHEC-infected T84 cells. SB 203580 89-97 C-X-C motif chemokine ligand 8 Homo sapiens 161-165 12667212-8 2003 Evaluation of IL-8 and MCP-1 RNA messages by reverse transcription-polymerase chain reaction (RT-PCR) revealed that the inhibitory effect of SB 203580 was associated with a reduction in this parameter. SB 203580 141-150 C-X-C motif chemokine ligand 8 Homo sapiens 14-18 12126643-8 2002 SB203580, a specific P38 MAPK inhibitor, partially blocked IL-1beta induction of IL-8 mRNA, IL-8 promoter activity, and AP-1 nuclear extract binding but not NF-kappaB DNA binding. SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 81-85 12126643-8 2002 SB203580, a specific P38 MAPK inhibitor, partially blocked IL-1beta induction of IL-8 mRNA, IL-8 promoter activity, and AP-1 nuclear extract binding but not NF-kappaB DNA binding. SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 92-96 12697421-5 2003 The induced IL-8 and MCP-1 proteins were almost completely supporessed by U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, or by SB203580, a selective p38 inhibitor. SB 203580 155-163 C-X-C motif chemokine ligand 8 Homo sapiens 12-16 12667212-5 2003 The production of IL-8 and monocyte chemotactic protein 1 (MCP-1) was attenuated by 50% when these cells were preincubated with the p38 MAPK inhibitor, SB 203580. SB 203580 152-161 C-X-C motif chemokine ligand 8 Homo sapiens 18-22 12091253-6 2002 The blockade of p38 with the pharmacologic inhibitor SB203580 abrogated IL-8 production by cell stretching, and an inhibitor of the p44/42 pathway, PD98059, partially inhibited the IL-8 response. SB 203580 53-61 C-X-C motif chemokine ligand 8 Homo sapiens 72-76 11966773-8 2002 The MAPK p38 appears necessary for the regulation of IL-8, GRO-alpha and GRO-beta expression as shown by inhibition with SB203580. SB 203580 121-129 C-X-C motif chemokine ligand 8 Homo sapiens 53-57 11562079-8 2001 PD98059 and SB203580, known as a specific inhibitor of MEKI and p38 kinase, respectively, inhibited IL-8 gene expression showing that both of the kinase pathways are involved in IL-8 regulation in human monocytes. SB 203580 12-20 C-X-C motif chemokine ligand 8 Homo sapiens 100-104 11562079-8 2001 PD98059 and SB203580, known as a specific inhibitor of MEKI and p38 kinase, respectively, inhibited IL-8 gene expression showing that both of the kinase pathways are involved in IL-8 regulation in human monocytes. SB 203580 12-20 C-X-C motif chemokine ligand 8 Homo sapiens 178-182 11028659-8 2000 Furthermore, PD98059 or SB203580 significantly suppressed BK-induced IL-6 and IL-8 production and their gene expression. SB 203580 24-32 C-X-C motif chemokine ligand 8 Homo sapiens 78-82 11084285-5 2000 In addition, incubation with the synthetic glucocorticoid dexamethasone or suppression of activity of p38 mitogen-activated protein (MAP) kinases by SB-203580 modulated release of IL-8. SB 203580 149-158 C-X-C motif chemokine ligand 8 Homo sapiens 180-184 11527995-9 2001 SB203580 inhibition of the p38 mitogen-activated protein kinase (MAPK) pathway significantly decreased zymosan-induced IL-8 mRNA accumulation. SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 119-123 11468165-5 2001 Using the selective p38 MAPK inhibitor SB203580, there was a significant decrease in thrombin-induced interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) protein production and messenger RNA steady-state levels. SB 203580 39-47 C-X-C motif chemokine ligand 8 Homo sapiens 102-115 11468165-5 2001 Using the selective p38 MAPK inhibitor SB203580, there was a significant decrease in thrombin-induced interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) protein production and messenger RNA steady-state levels. SB 203580 39-47 C-X-C motif chemokine ligand 8 Homo sapiens 117-121 11468165-6 2001 In addition, SB203580 decreased IL-8 and MCP-1 production induced by the thrombin receptor-1 agonist peptide (TRAP), suggesting functional links between the thrombin G protein-coupled receptor and the p38 MAPK pathway. SB 203580 13-21 C-X-C motif chemokine ligand 8 Homo sapiens 32-36 10873157-5 2000 Expression of IL-6 and IL-8 was sensitive to SB203580, the specific inhibitor of p38 mitogen-activated protein (MAP) kinase and PD98059, an inhibitor of MAP kinase kinase. SB 203580 45-53 C-X-C motif chemokine ligand 8 Homo sapiens 23-27 10722601-8 2000 The release of interleukin-8 was markedly suppressed by the p38 mitogen-activated protein kinase inhibitor SB203580 but was only minimally suppressed by the mitogen-activated protein/extracellular signal-regulated kinase inhibitor PD98059. SB 203580 107-115 C-X-C motif chemokine ligand 8 Homo sapiens 15-28 10773004-7 2000 The results showed that LPS induced p38 MAP kinase phosphorylation and activity, and SB 203580 as a selective inhibitor of p38 MAP kinase activity inhibited p38 MAP kinase activity and IL-8 expression in LPS-stimulated pulmonary vascular endothelial cells. SB 203580 85-94 C-X-C motif chemokine ligand 8 Homo sapiens 185-189 10620700-2 2000 Pretreatment of RSF with a specific p38 MAP kinase inhibitor, SB203580, blocked the induction of IL-6 and IL-8 without affecting nuclear translocation of nuclear factor kappaB (NF-kappaB) or IL-6 and IL-8 mRNA levels. SB 203580 62-70 C-X-C motif chemokine ligand 8 Homo sapiens 106-110 10619832-6 2000 SB 203580, as the specific inhibitor of p38 MAP kinase activity, inhibited DEP-induced IL-8 and RANTES production. SB 203580 0-9 C-X-C motif chemokine ligand 8 Homo sapiens 87-91 35352794-10 2022 Furthermore, p38 inhibitor SB203580 inhibited the production and secretion of TNF-alpha, IL-1beta and IL-8 in THP-1 cells treated with LPS. SB 203580 27-35 C-X-C motif chemokine ligand 8 Homo sapiens 102-106 10455891-5 1999 RESULTS: Priming by tumor necrosis factor alpha (TNF-alpha), interleukin-8 (IL-8), and granulocyte-macrophage colony-stimulating factor (GM-CSF) was significantly inhibited by SB203580, whereas platelet-activating factor (PAF) priming was unaffected. SB 203580 176-184 C-X-C motif chemokine ligand 8 Homo sapiens 61-74 9927384-5 1999 SB 203580 as the specific p38 MAP kinase inhibitor inhibited hyperosmolarity-induced p38 MAP kinase activation and partially inhibited hyperosmolarity-induced IL-8 expression. SB 203580 0-9 C-X-C motif chemokine ligand 8 Homo sapiens 159-163 9916078-5 1999 By using PD-98059 and SB203580, two potent and selective inhibitors of MEK1 (a kinase upstream of ERK1/2) and p38, respectively, we have demonstrated that both ERK1/2 and p38 cascades play a key role in the production of IL-8 by monocytes and PMN stimulated with bacterial fractions. SB 203580 22-30 C-X-C motif chemokine ligand 8 Homo sapiens 221-225 9648711-6 1998 The specific p38 MAP kinase inhibitor, SB 203580, completely inhibited TNF-alpha-, IL-1alpha-, or PAF-induced IL-8 protein and mRNA expression in BECs. SB 203580 39-48 C-X-C motif chemokine ligand 8 Homo sapiens 110-114 10445612-2 1999 To this end, the phosphorylation and activation of p38 MAP kinase and the effect of SB 203580, a specific inhibitor of p38 MAP kinase activity, on p38 MAP kinase activity and IL-8 expression in TNF-alpha- and IL-1alpha-stimulated human pulmonary vascular endothelial cells were examined. SB 203580 84-93 C-X-C motif chemokine ligand 8 Homo sapiens 175-179 10445612-4 1999 Inhibition of TNF-alpha- and IL-1alpha-induced p38 MAP kinase activity by SB 203580 inhibited TNF-alpha- and IL-1alpha-induced IL-8 protein production as well as IL-8 messenger ribonucleic acid (mRNA) expression, indicating that SB 203580 was effective at the transcriptional level. SB 203580 74-83 C-X-C motif chemokine ligand 8 Homo sapiens 127-131 9705848-5 1998 The specific p38 MAP kinase inhibitor SB 203580 inhibited cooling and rewarming-induced IL-8 expression, indicating that cooling and rewarming-induced IL-8 expression in BEC was mediated through p38 MAP kinase-dependent pathway. SB 203580 38-47 C-X-C motif chemokine ligand 8 Homo sapiens 88-92 9705848-5 1998 The specific p38 MAP kinase inhibitor SB 203580 inhibited cooling and rewarming-induced IL-8 expression, indicating that cooling and rewarming-induced IL-8 expression in BEC was mediated through p38 MAP kinase-dependent pathway. SB 203580 38-47 C-X-C motif chemokine ligand 8 Homo sapiens 151-155 26820827-6 2016 5-HT-induced elevation of IL-8 at both mRNA and protein levels was observed, which was inhibited by TEMPOL (a free radical scavenger), and inhibitors for p38 MAPK (SB203580) and ERK (U0126), in line with the time-dependent phosphorylation of p38 MAPK and ERK. SB 203580 164-172 C-X-C motif chemokine ligand 8 Homo sapiens 26-30 34971958-10 2022 The p38 inhibitor SB203580 inhibited the secretion of IL-8, slightly inhibited the secretion of IL-6, and did not affect NF-kappaB activity. SB 203580 18-26 C-X-C motif chemokine ligand 8 Homo sapiens 54-58 30558829-11 2019 SB203580 showed little effect on IL-1beta-induced sICAM-1 secretion, but effectively inhibited its induction of IL-8 secretion in pulp cells. SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 112-116 33860562-8 2021 SB203580, a p38 pathway inhibitor, decreased the expression of CXCL8 in sebocytes after ALA-PDT. SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 63-68 31766770-10 2019 BIRB796 and SB203580 reduced TNFalpha-induced IL-8. SB 203580 12-20 C-X-C motif chemokine ligand 8 Homo sapiens 46-50 31766770-11 2019 SB203580 reduced LPS-induced IL-8. SB 203580 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 29-33 31766770-13 2019 All combinations including fluticasone/SB203580 reduced LPS-induced IL-8 stronger than single treatments. SB 203580 39-47 C-X-C motif chemokine ligand 8 Homo sapiens 68-72 33441226-8 2021 Interestingly, while SB203580 inhibited the activation of p38 MAPK signaling pathway, it only inhibited the mRNA levels of IL-6 and IL-8 in HDM-induced 16HBE cells, but had no effect on their protein levels. SB 203580 21-29 C-X-C motif chemokine ligand 8 Homo sapiens 132-136 31729901-7 2020 Moreover, p38/MAPK inhibitor SB203580 and NF-kappaB inhibitor BAY11-7082 could block the IL-8 up-regulated by X-rays but JNK inhibitor SP600125, ERK inhibitor U0126, ROS Scavenger NAC could not inhibit this phenomenon.Conclusions: X-rays could induce IL-8 production in lung cancer cells, which may be related to the activation of p38/MAPK and NF-kappaB signaling pathway, providing a new point for elucidating the mechanism of radiation pneumonitis. SB 203580 29-37 C-X-C motif chemokine ligand 8 Homo sapiens 89-93 31729901-7 2020 Moreover, p38/MAPK inhibitor SB203580 and NF-kappaB inhibitor BAY11-7082 could block the IL-8 up-regulated by X-rays but JNK inhibitor SP600125, ERK inhibitor U0126, ROS Scavenger NAC could not inhibit this phenomenon.Conclusions: X-rays could induce IL-8 production in lung cancer cells, which may be related to the activation of p38/MAPK and NF-kappaB signaling pathway, providing a new point for elucidating the mechanism of radiation pneumonitis. SB 203580 29-37 C-X-C motif chemokine ligand 8 Homo sapiens 251-255 32069432-6 2020 MCP-1 and GM-CSF levels, as well as gene expressions of IL-6 and IL-8 in HTR8/SVneo cells were greatly increased by TNF-alpha (5, 10 and 20 ng/mL), but reversed by sevoflurane and SB203580. SB 203580 180-188 C-X-C motif chemokine ligand 8 Homo sapiens 65-69 30022772-7 2018 The gamma-irradiation-induced increase in IL-6 and IL-8 production was suppressed by apyrase (ecto-nucleotidase), NF157 (selective P2Y11 receptor antagonist) and SB203580 (p38 MAPK inhibitor). SB 203580 162-170 C-X-C motif chemokine ligand 8 Homo sapiens 51-55 29412148-6 2018 A specific inhibitor of p38MAPK, SB203580 significantly decreased the secretion of IL-6 and IL-8, the major components of SASPs. SB 203580 33-41 C-X-C motif chemokine ligand 8 Homo sapiens 92-96 29660434-8 2018 BDP/FOR and SB203580 showed the highest inhibitory effect on epithelial IL-8, whereas endothelial ICAM-1 was never affected by BDP/FOR and PDTC. SB 203580 12-20 C-X-C motif chemokine ligand 8 Homo sapiens 72-76 29245047-6 2018 Conversely, pretreatment with SB203580, a selective inhibitor of p38 MAPK, blocked p38 MAPK phosphorylation and IL-6 and IL-8 expression. SB 203580 30-38 C-X-C motif chemokine ligand 8 Homo sapiens 121-125 28288823-12 2017 Pretreatment with U0126-an inhibitor of MEK1 and MEK2 kinases-SB203580-a p38 MAPK inhibitor-and SC-514-an IKKbeta inhibitor-suppressed cadmium-induced IL-8 expression and release. SB 203580 62-70 C-X-C motif chemokine ligand 8 Homo sapiens 151-155 28176455-12 2017 Additionally, WZ4003 and SB203580 could suppress the APN-induced overexpression of CXCL1 and CXCL8. SB 203580 25-33 C-X-C motif chemokine ligand 8 Homo sapiens 93-98 27988394-5 2017 UFP-induced IL-8 could be reduced by SB203580, indicating a role of p38MAPK activation in IL-8 production. SB 203580 37-45 C-X-C motif chemokine ligand 8 Homo sapiens 12-16 27988394-5 2017 UFP-induced IL-8 could be reduced by SB203580, indicating a role of p38MAPK activation in IL-8 production. SB 203580 37-45 C-X-C motif chemokine ligand 8 Homo sapiens 90-94